Nutriband (NASDAQ:NTRB) & Pathfinder Cell Therapy (OTCMKTS:PFND) Head to Head Survey

Nutriband (NASDAQ:NTRB) and Pathfinder Cell Therapy (OTCMKTS:PFND) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Nutriband and Pathfinder Cell Therapy”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.02 million	36.97	-$5.49 million	($0.71)	-9.48
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A

Pathfinder Cell Therapy has lower revenue, but higher earnings than Nutriband.

Profitability

This table compares Nutriband and Pathfinder Cell Therapy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutriband	-338.51%	-54.49%	-48.52%
Pathfinder Cell Therapy	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Nutriband and Pathfinder Cell Therapy, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	0	0	1	0	3.00
Pathfinder Cell Therapy	0	0	0	0	0.00

Nutriband currently has a consensus price target of $13.00, suggesting a potential upside of 93.16%. Given Nutriband’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Nutriband is more favorable than Pathfinder Cell Therapy.

Insider and Institutional Ownership

19.7% of Nutriband shares are owned by institutional investors. 54.1% of Nutriband shares are owned by insiders. Comparatively, 15.1% of Pathfinder Cell Therapy shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Nutriband beats Pathfinder Cell Therapy on 6 of the 9 factors compared between the two stocks.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.